Pegylated Liposomal Doxorubicin (Caelyx<sup>®</sup>) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial

Pegylated Liposomal Doxorubicin (Caelyx<sup>®</sup>) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial

Background: Adjuvant chemotherapy for Luminal B-like breast cancers usually includes anthracycline-based regimens. However, some patients are reluctant to receive chemotherapy because of side-effects, especially alopecia, and ask for a “less intensive” or personalized approach. Patients and methods:...

Full description

Bibliographic Details
Main Authors: Silvia Dellapasqua, Pamela Trillo Aliaga, Elisabetta Munzone, Vincenzo Bagnardi, Eleonora Pagan, Emilia Montagna, Giuseppe Cancello, Raffaella Ghisini, Claudia Sangalli, Mara Negri, Manuelita Mazza, Monica Iorfida, Anna Cardillo, Angela Sciandivasci, Nadia Bianco, Ana Paula De Maio, Monica Milano, Giuseppe Maria Campennì, Loredana Sansonno, Giuseppe Viale, Anna Morra, Maria Cristina Leonardi, Viviana Galimberti, Paolo Veronesi, Marco Colleoni
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Current Oncology
Subjects:
adjuvant chemotherapy
early breast cancer
luminal B-like subtypes
pegylated liposomal doxorubicin (PLD)
Caelyx<sup>®</sup>
Online Access:https://www.mdpi.com/1718-7729/28/6/433

Internet

https://www.mdpi.com/1718-7729/28/6/433

Similar Items